Late preconditioning against myocardial stunning. Does aspirin close the "second window" of endogenous cardioprotection?
Przyklenk
Karin
K
Heusch
Gerd
G
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology*; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D004195:Disease Models, Animal; D006801:Humans; D019157:Ischemic Preconditioning, Myocardial; D007527:Isoenzymes / Q000187:drug effects*; D008565:Membrane Proteins; D009203:Myocardial Infarction / Q000503:physiopathology / Q000517:prevention & control; D017682:Myocardial Stunning / Q000188:drug therapy / Q000503:physiopathology*; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects* / Q000502:physiology; D011817:Rabbits
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D001241:Aspirin